Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

Ozempic was originally approved to treat people with Type 2 diabetes, but demand has surged because of the drug’s weight-loss ...

Whether to fully subsidise the new generation weight loss drugs such as Mounjaro and Ozempic for obese Australians without ...

Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...

BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...